Discover the latest insights on the long-term effectiveness of innovative psoriasis treatments through a comprehensive network meta-analysis of PASI score persistence over 5 years.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Assessing the 5-year persistence in positive clinical response with innovative psoriasis treatments: a network meta-analysis of pasi score.
Husein-ElAhmed et al., Clin Exp Dermatol 2024
<!– DOI: 10.1093/ced/llae131 //–>
https://doi.org/10.1093/ced/llae131
This study provides a comprehensive analysis of the long-term effectiveness of biologic agents in treating psoriasis, focusing on their ability to maintain optimal and suboptimal clinical responses over a 5-year period. Through a systematic review and network meta-analysis (NMA) of 18 randomized controlled trials (RCTs) involving 11,202 patients, the research identifies guselkumab, ixekizumab, and risankizumab as the top performers in sustaining high levels of clinical remission (persistence at optimal response, POR) and low disease activity (persistence at suboptimal response, PSR). Specifically, guselkumab leads with the highest cumulative probabilities of POR (0.8397250) and PSR (0.86083636), followed closely by ixekizumab and risankizumab. In contrast, etanercept, brodalumab, apremilast, and placebo rank lowest in both categories. This study highlights the superior long-term efficacy of certain biologics in psoriasis treatment and introduces POR and PSR as valuable metrics for assessing sustained clinical outcomes, suggesting a need for further validation of these measures.